Shares mag. recommending this stock this week. Is this going to be our killer this christmas!!!! any comments anyone?????

I was, and I shall be tonight. Seasonal Greetings one and all. & CENES post those results and put me out of my misery.

And to you Jobi. Have a good night.I'm sure CEN will buy you a drink!

Onward & upwards.

Although this time last year the sp headed north & fell back. If we have some good news as expected this month, we should see some exceptional gains this year.

Best wishes to & good luck to one & all for '07.

Added some more yesterday. Hopefully news soon.

CEN could blow any day now.

M6G results probably within 4 weeks imo.

Objective Capital gave CeNeS a Fair Value of 27p last month:

http://www.proactiveinvestors.co.uk/registered/research/objective-cenes-dec06.pdf

Bless them!

CEN said it could receive up to 5 mln usd in milestone payments over the next few years if trials of its experimental smoking cessation drug, being carried out by a licensee, prove successful.

The group out licensed the selective dopamine D1 receptor antagonist, called ADX10061, to Addex Pharmaceuticals in 2002. The group has now started a phase IIa study in the US, and positive results will trigger the payments to CEN.

The company would also receive annual royalties on sales, should ADX10061 reach the market.

'Whilst we are not guaranteed success from any of our carried interests the chance of realising a financial return from Addex is much increased as a result of them commencing this phase II trial,' CEN chief executive Neil Clark said in a statement.

Hi queen1 Your post is indeed good news for the company and the investors

The big news should be out soon.. CeNeS M6G022 Phase III study on treatment with either M6G or Morphine. Effective analgesic could result in lower levels of nausea in patients receiving M6G compared to those receiving morphine. Keep your eyes on this company.

Indeed myway - They've steadied over 8p which they haven't done for a couple of years now so my eyes are firmly fixed on next moves!

This is from the CeNeS site. The results could be announced anytime

Phase III trials of M6G

CeNeS is also pleased to announce that it has successfully completed patient recruitment in its pivotal Phase III trial with M6G in Europe (Study M6G022) for the treatment of post operative pain. The study enrolled over 500 patients at 24 centres in six countries. Results from the study are expected in early 2007.

J

CeNeS 5 February 2007 The Goldman Sachs Group, Inc. ("GS Inc."), had an interest in 38,960,863 ordinary shares of 1p each in the capital of the Company. This interest arose from a beneficial interest held by Goldman Sachs International Limited, a wholly-owned indirect subsidiary of GS Inc. This shareholding represents 8.1 per cent. of the issued share capital of the Company.

They only buy for profit..

If on 4/12/2007 CEN reported the PIII M6G EU trial complete, they should have received the results by now and be on the verge of publicising.

If the results are good, these could be worth more than 40p.

I telephoned CEN today and was told Neil Clark is on holiday until Friday (this is currently school half-term) so I do not expect any news regarding the Phase 3 M6G results this week.

Maybe next week ?

The good news is out today. M6G successful in phase III European trials.

:-)

12p today maybe. I think end results hit all targets --- 25% improvement over morphine was needed --- got 28% ---- phew! Close but enough for c150m-200m sales -- my guess. That's enough for c12p alone for CEn let alone other pipeline which looks nice too

Get in - come on baby!

Looking very good.

It feels good when the patience starts to pay off. Good luck too all.

J